Belantamab mafodotinevents and moves- 20 Apr 2026 GlaxoSmithKline: BLENREP APPROVED IN CHINA FOR 2L+ MULTIPLE MYELOMA own move -0.8%, next session -1.1%
- 2026-04 NMPA approval: With bortezomib and dexamethasone (BVd) for relapsed or refractory multiple myeloma after at least one prior line own move +0.7%, next session +1.9%
- 24 Oct 2025 GlaxoSmithKline: BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA own move -5.0%, next session +1.1%
- 23 Oct 2025 FDA approval: BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. own move +2.8%, next session -5.0%
- 23 Oct 2025 Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma own move +2.8%, next session -5.0%
- 24 Jul 2025 GlaxoSmithKline: BLENREP APPROVED IN THE EU FOR MULTIPLE MYELOMA own move +0.9%, next session -1.2%
- 23 Jul 2025 EC/EMA approval: Adults with relapsed or refractory multiple myeloma: with bortezomib plus dexamethasone, or with pomalidomide plus dexamethasone own move +0.7%, next session +0.9%
- 23 Jul 2025 GlaxoSmithKline: US FDA REVIEW EXTENDED FOR BLENREP own move +0.7%, next session +0.9%
- 18 Jul 2025 GlaxoSmithKline: BLENREP US ODAC OUTCOME own move +0.2%, next session +0.3%
- 23 May 2025 GlaxoSmithKline: POSITIVE CHMP OPINION ON BLENREP IN EU own move -0.5%, next session +0.6%
- 19 May 2025 GlaxoSmithKline: BLENREP FOR 2L+ MULTIPLE MYELOMA APPROVED IN JAPAN own move -0.1%, next session +0.9%
- 2025-05 MHLW approval: Relapsed or refractory multiple myeloma: Blenrep with bortezomib plus dexamethasone, or with pomalidomide plus dexamethasone own move -0.0%, next session -0.6%
- 17 Apr 2025 MHRA approval: Adults with relapsed or refractory multiple myeloma: with bortezomib plus dexamethasone, or with pomalidomide plus dexamethasone own move +2.2%, next session +3.6%
- 17 Apr 2025 GlaxoSmithKline: BLENREP LICENSED BY UK MHRA own move +2.2%, next session +3.6%
- 9 Dec 2024 GlaxoSmithKline: BLENREP COMBINATION CHINA FILING ACCEPTANCE own move +3.8%, next session -1.8%
| 17 | 6% |
Zidesamtinibevents and moves- 18 Sep 2026 PDUFA target action date set for September 18, 2026 own move -1.4%, next session +1.3%
- 13 Sep 2026 GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer own move +2.5%, next session -0.0%
- 22 Jul 2026 FDA approval: adult patients with locally advanced or metastatic ROS 1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor own move +0.5%, next session -1.3%
- 22 Jul 2026 FDA approval: JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor. own move +0.5%, next session -1.3%
- 22 Jul 2026 Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer own move +0.5%, next session -1.3%
- 21 May 2026 Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting own move +0.8%, next session -1.5%
- 21 Apr 2026 New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 own move -1.1%, next session -1.1%
- 17 Apr 2026 New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 own move +0.6%, next session -0.8%
- 7 Apr 2026 Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 own move -1.1%, next session +0.6%
- 17 Mar 2026 Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 own move +0.2%, next session -0.9%
- 12 Jan 2026 Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones own move -0.0%, next session -0.6%
- 19 Nov 2025 Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC own move -2.0%, next session +0.1%
- 4 Nov 2025 Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer own move +0.6%, next session -0.7%
- 7 Sep 2025 Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 own move -1.1%, next session +1.3%
- 13 Aug 2025 Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium own move +0.8%, next session -0.2%
| 20 | 3% |
Mepolizumab (Nucala)events and moves- 6 Feb 2026 EMA / European Commission approval: Add-on maintenance treatment in adults for uncontrolled COPD characterised by raised blood eosinophils own move -0.1%, next session -1.1%
- 6 Feb 2026 Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD) own move -0.1%, next session -1.1%
- 6 Feb 2026 GlaxoSmithKline: NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION own move -0.1%, next session -1.1%
- 5 Jan 2026 Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD) own move -0.9%, next session +1.2%
- 5 Jan 2026 GlaxoSmithKline: NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA own move -0.9%, next session +1.2%
- 2026-01 NMPA approval: Add-on maintenance treatment for inadequately controlled COPD own move +0.7%, next session -0.9%
- 12 Dec 2025 Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease (COPD) own move -0.5%, next session -0.4%
- 12 Dec 2025 GlaxoSmithKline: NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD own move -0.5%, next session -0.4%
- 23 May 2025 GlaxoSmithKline: FDA APPROVES NUCALA COPD INDICATION own move -0.5%, next session +0.6%
- 22 May 2025 FDA approval: NUCALA is indicated for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. own move +1.8%, next session -0.5%
- 1 May 2025 GlaxoSmithKline: NUCALA MATINEE DATA IN COPD PUBLISHED IN NEJM own move -0.0%, next session -0.6%
- 24 Mar 2025 GlaxoSmithKline: EMA FILING ACCEPTANCE FOR NUCALA COPD own move -2.1%, next session +1.3%
- 20 Feb 2025 GlaxoSmithKline: NUCALA COPD SUBMISSION ACCEPTED IN CHINA own move +0.6%, next session -0.3%
- 3 Jan 2025 GlaxoSmithKline: GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP own move -2.4%, next session +1.4%
- 9 Dec 2024 GlaxoSmithKline: NUCALA COPD SUBMISSION ACCEPTED BY US FDA own move +3.8%, next session -1.8%
| 13 | 3% |
Depemokimabevents and moves- 15 Jun 2026 Health Canada approval: Asthma EXDENSUR (depemokimab injection) is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma characterized by an eosinophilic phenotype and inadequately controlled by medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller. EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus (See 7 Warnings and Precautions). Chronic rhinosinusitis with nasal polyps EXDENSUR is indicated as an add-on maintenance treatment with intranasal corticosteroids in adults with severe chronic... own move -0.9%, next session -0.1%
- 8 Apr 2026 Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) own move +0.6%, next session +2.0%
- 30 Mar 2026 NMPA approval: Add-on maintenance treatment of severe asthma (Exdensur) own move +0.3%, next session -0.2%
- 30 Mar 2026 Exdensur (depemokimab) approved in China for the treatment of severe asthma own move +0.3%, next session -0.2%
- 17 Feb 2026 Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps own move +3.5%, next session +0.3%
- 12 Feb 2026 EMA/European Commission approval: Asthma Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic rhinosinusitis with nasal polyps (CRSwNP) Exdensur is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease... own move +0.2%, next session -0.4%
- 6 Jan 2026 Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps own move +1.2%, next session -0.9%
- 22 Dec 2025 PMDA approval: Treatment of bronchial asthma (for use only in patients with severe or intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies) and chronic rhinosinusitis with nasal polyps (for use only in patients who have not responded sufficiently to conventional treatments) own move -0.3%, next session +0.7%
- 17 Dec 2025 GlaxoSmithKline: EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA own move +0.0%, next session -0.9%
- 16 Dec 2025 FDA approval: EXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. own move +0.4%, next session +0.0%
- 16 Dec 2025 Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma own move +0.4%, next session +0.0%
- 16 Dec 2025 GlaxoSmithKline: EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL own move +0.4%, next session +0.0%
- 15 Dec 2025 MHRA approval: Exdensur: asthma with type 2 inflammation, and chronic rhinosinusitis with nasal polyps (UK marketing authorisation) own move -0.4%, next session +0.4%
- 15 Dec 2025 Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps own move -0.4%, next session +0.4%
- 12 Dec 2025 GlaxoSmithKline: DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION own move -0.5%, next session -0.4%
| 15 | 2% |
Dostarlimabevents and moves- 26 Oct 2026 GlaxoSmithKline: JEMPERLI DATA SHOW 76% COMPLETE RESPONSE RATE own move +0.7%, next session -0.3%
- 19 Oct 2026 FDA approves Jemperli under accelerated approval in dMMR locally advanced rectal cancer own move +0.5%, next session -0.0%
- 19 Oct 2026 FDA approval: adults with Stage II/III locally advanced rectal cancer that is microsatellite-instability-high (MSI-H) or deficient mismatch repair (dMMR), as determined by an FDA authorized test for solid tumors. own move +0.5%, next session -0.0%
- 19 Oct 2026 FDA approval: JEMPERLI (dostarlimab-gxly): adults with stage II or III mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced rectal cancer (accelerated approval) own move +0.5%, next session -0.0%
- 24 Aug 2026 GlaxoSmithKline: US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER own move -1.2%, next session +0.2%
- 24 Aug 2026 Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer own move -1.2%, next session +0.2%
- 13 Jul 2026 Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer own move -1.3%, next session -0.1%
- 13 Jul 2026 GlaxoSmithKline: POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER own move -1.3%, next session -0.1%
- 6 Aug 2025 COSTAR Lung (NCT04655976) did not meet its overall survival primary endpoint own move -0.0%, next session +3.4%
- 21 Jan 2025 GlaxoSmithKline: JEMPERLI EXPANDED APPROVAL IN THE EU own move -0.6%, next session -0.8%
- 20 Dec 2024 FIRST trial meets primary PFS endpoint own move -0.8%, next session +0.8%
- 16 Dec 2024 GlaxoSmithKline: JEMPERLI RECEIVES POSITIVE CHMP OPINION own move +0.1%, next session +2.0%
- 16 Dec 2024 GlaxoSmithKline: JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION own move +0.1%, next session +2.0%
- 2 Aug 2024 GlaxoSmithKline: FDA EXPANDS JEMPERLI APPROVAL own move +2.2%, next session +0.1%
| 9 | 2% |
neladalkibevents and moves- 21 May 2026 Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting own move +0.8%, next session -1.5%
- 21 Apr 2026 Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting own move -1.1%, next session -1.1%
- 7 Apr 2026 Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC own move -1.1%, next session +0.6%
- 17 Nov 2025 Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC own move +0.8%, next session -0.9%
- 14 Nov 2025 Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib own move -1.4%, next session +0.8%
- 18 Oct 2025 Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025 own move -0.6%, next session -0.6%
- 21 Jul 2025 Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC own move +0.3%, next session +0.4%
- 23 Apr 2025 Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting own move +0.6%, next session +0.0%
- 25 Mar 2025 Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 own move +1.3%, next session -0.3%
- 13 Sep 2024 Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 own move -0.4%, next session +0.6%
- 9 Sep 2024 Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles own move -0.1%, next session -0.1%
- 16 Jul 2024 Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 own move -0.8%, next session +2.0%
| 12 | 1% |
Efimosfermin alfaevents and moves | 3 | shown from 8 days |
NVL-330events and moves | 3 | shown from 8 days |
fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta)events and moves | 2 | shown from 8 days |
Salbutamol HFA-152aevents and moves | 2 | shown from 8 days |
Risvutatug rezetecanevents and moves | 2 | shown from 8 days |
HS235events and moves | 1 | shown from 8 days |
Belantamabevents and moves | 1 | shown from 8 days |
fluticasone propionateevents and moves | 1 | shown from 8 days |
albuterol (Ventolin) (Ventolin)events and moves | 1 | shown from 8 days |
BLU-5937events and moves | 1 | shown from 8 days |
Niraparibevents and moves | 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 4% |
| Other company news (earnings, financing, releases naming no asset) | — | 69% |
| Sessions with no dated event | — | 9% |